Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 1586

1.

Pharmacotherapy of Down syndrome.

Palumbo ML, McDougle CJ.

Expert Opin Pharmacother. 2018 Sep 26:1-15. doi: 10.1080/14656566.2018.1529167. [Epub ahead of print]

PMID:
30257591
2.

Pharmacological management of depression in patients with multiple sclerosis.

Carta MG, Paribello P, Anastasia A, De Berardis D, Nardi AE, Fornaro M.

Expert Opin Pharmacother. 2018 Oct;19(14):1533-1540. doi: 10.1080/14656566.2018.1516207. Epub 2018 Sep 12. Review.

PMID:
30207800
3.

Dosage-related nature of escitalopram treatment-emergent mania/hypomania: a case series.

Yamaguchi Y, Kimoto S, Nagahama T, Kishimoto T.

Neuropsychiatr Dis Treat. 2018 Aug 17;14:2099-2104. doi: 10.2147/NDT.S168078. eCollection 2018.

4.

Simultaneous analysis of olanzapine, fluoxetine, and norfluoxetine in human plasma using liquid chromatography-mass spectrometry and its application to a pharmacokinetic study.

Ni XJ, Wang ZZ, Shang DW, Lu HY, Zhang M, Wen YG.

J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Aug 15;1092:506-514. doi: 10.1016/j.jchromb.2018.05.026. Epub 2018 May 18.

PMID:
30008307
5.

Antipsychotic discontinuation after the initiation of selective serotonin reuptake inhibitors therapy for the treatment of behavioral and psychological symptoms associated with dementia.

Mathys M, Fang S, John J, Carter J.

Ment Health Clin. 2018 Apr 26;8(3):122-126. doi: 10.9740/mhc.2018.05.122. eCollection 2018 May.

6.

Possible SAMe-induced mania.

Abeysundera H, Gill R.

BMJ Case Rep. 2018 Jun 27;2018. pii: bcr-2018-224338. doi: 10.1136/bcr-2018-224338.

PMID:
29950497
7.

Antiepileptic effect of olanzapine in epilepsy patients with atypical depressive comorbidity.

Qiu X, Zingano B, He S, Zhu X, Peng A, Duan J, Wolf P, Chen L.

Epileptic Disord. 2018 Jun 1;20(3):225-231. doi: 10.1684/epd.2018.0977.

PMID:
29905158
8.

Evaluation of antioxidant potencial of novel CaAl and NiAl layered double hydroxides loaded with olanzapine.

Pontes-Neto JG, Fontes DAF, de Lyra MAM, Brito MDRM, Chaves LL, Rolim-Neto PJ, De La Roca Soares MF, Quintans Júnior LJ, de Freitas RM, Soares-Sobrinho JL.

Life Sci. 2018 Aug 15;207:246-252. doi: 10.1016/j.lfs.2018.05.031. Epub 2018 May 17.

PMID:
29778806
9.

The circulating levels of CD4+ t helper cells are higher in bipolar disorder as compared to major depressive disorder.

Becking K, Haarman BCM, Grosse L, Nolen WA, Claes S, Arolt V, Schoevers RA, Drexhage HA.

J Neuroimmunol. 2018 Jun 15;319:28-36. doi: 10.1016/j.jneuroim.2018.03.004. Epub 2018 Mar 21.

PMID:
29685287
10.

Secondary mania following cancer chemotherapy with capecitabine.

Garg H, Prakash S, Deb KS, Chadda RK.

BMJ Case Rep. 2018 Mar 28;2018. pii: bcr-2017-220995. doi: 10.1136/bcr-2017-220995.

PMID:
29599381
11.

Plasma C-reactive protein levels in bipolar depression during cyclooxygenase-2 inhibitor combination treatment.

Edberg D, Hoppensteadt D, Walborn A, Fareed J, Sinacore J, Halaris A.

J Psychiatr Res. 2018 Jul;102:1-7. doi: 10.1016/j.jpsychires.2018.02.004. Epub 2018 Feb 13.

PMID:
29554535
12.

Fatal intoxication with antidepressants: a case with many culprits.

Goulas A, Raikos N, Krokos D, Mastrogianni O, Orphanidis A, Zisopoulos K, Tsepa A.

Forensic Sci Med Pathol. 2018 Jun;14(2):225-228. doi: 10.1007/s12024-018-9960-3. Epub 2018 Feb 27.

PMID:
29488058
13.

Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse.

Temmingh HS, Williams T, Siegfried N, Stein DJ.

Cochrane Database Syst Rev. 2018 Jan 22;1:CD011057. doi: 10.1002/14651858.CD011057.pub2. Review.

PMID:
29355909
14.

[Trazodone prolonged release in bipolar disorder II-obsessive-compulsive disorder comorbidity: a case report].

Lorettu L, Meli G, Antonioli E, Zeppa A, Milia P, Nivoli A.

Riv Psichiatr. 2017 Nov-Dec;52(6):255-257. doi: 10.1708/2846.28729. Italian.

PMID:
29343875
15.

Metabolic risk factors in schizophrenia and bipolar disorder: The effect of comedication with selective serotonin reuptake inhibitors and antipsychotics.

Fjukstad KK, Engum A, Lydersen S, Dieset I, Steen NE, Andreassen OA, Spigset O.

Eur Psychiatry. 2018 Feb;48:71-78. doi: 10.1016/j.eurpsy.2017.04.001. Epub 2017 Apr 17.

PMID:
29331603
16.
17.

Molecular network-selected pharmacogenomics in a case of bipolar spectrum disorder.

Fortinguerra S, Buriani A, Sorrenti V, Lenzi M, Giusti P.

Pharmacogenomics. 2017 Dec;18(18):1631-1642. doi: 10.2217/pgs-2017-0133. Epub 2017 Nov 27.

PMID:
29173093
18.

A Review of Asenapine in the Treatment of Bipolar Disorder.

Vieta E, Montes JM.

Clin Drug Investig. 2018 Feb;38(2):87-99. doi: 10.1007/s40261-017-0592-2. Review.

19.

Pharmacogenomics in the treatment of mood disorders: Strategies and Opportunities for personalized psychiatry.

Amare AT, Schubert KO, Baune BT.

EPMA J. 2017 Sep 5;8(3):211-227. doi: 10.1007/s13167-017-0112-8. eCollection 2017 Sep. Review.

20.

Phelan-McDermid syndrome due to SHANK3 mutation in an intellectually disabled adult male: successful treatment with lithium.

Egger JIM, Verhoeven WMA, Groenendijk-Reijenga R, Kant SG.

BMJ Case Rep. 2017 Sep 28;2017. pii: bcr-2017-220778. doi: 10.1136/bcr-2017-220778.

PMID:
28963116

Supplemental Content

Loading ...
Support Center